Research use onlyNot for human or veterinary use
Encore Bio Labs CartExplore catalog
ENCORE BIO LABSRESEARCH COLLECTION
Tesamorelin — complete Encore Bio Labs reference vialMATERIAL / 22

Reference artwork · Legacy packaging may be shown.
Listed identity and formats take precedence over the image.

Research material

Tesamorelin

What starts the signal for hormone release? Tesamorelin brings that question into focus through its reference interaction with the GHRH receptor. Its modified peptide structure adds another point of interest: how molecular design connects with endocrine signaling.

CAS
218949-48-5

Formats & reference pricing

USD
Listed formatReference price
10 mg$75 USD

Reference prices describe the listed formats. They do not confirm availability or constitute an offer for sale.

Review product documentation

For laboratory research only. Not for human or veterinary use.

About the reference identity

A chain with a distinct end group

Public structural descriptions of tesamorelin show 44 amino-acid residues and a six-carbon hexenoyl group attached at the beginning of the chain. The attachment is part of the molecule's identity, alongside the sequence itself. Reference labeling describes a specific branded formulation, not the contents or equivalence of this catalog material.

Reference length
44 amino-acid residues
Structural detail
Six-carbon hexenoyl end group

Reference identity only; not a test result for current inventory.

01 / Material overview

The specifications.

Catalog identity
Tesamorelin
CAS
218949-48-5
Listed formats
10 mg
Reference price range
$75 USD
Intended setting
Qualified laboratory or institutional research
Inventory specifications
Independent inventory review pending

02 / Public regulatory context

Approved products and catalog boundaries.

Public FDA labeling can identify approved prescription products that contain tesamorelin. It does not convert this catalog material into an approved drug product.

REGULATORY REFERENCE · STATUS REVIEWED OCT 2026TESAMORELIN

FDA-approved branded products exist. This catalog material is separate.

FDA-approved prescription drug products containing tesamorelin are marketed under the EGRIFTA brand. The approved labeling applies to those specific labeled products and formulations. This Encore Bio Labs catalog listing is not represented as EGRIFTA, FDA-approved, interchangeable, substitutable, or equivalent in formulation, sterility, potency, manufacturing controls, quality, or intended use.

Catalog identity
Tesamorelin
CAS
218949-48-5
FDA-labeled products
EGRIFTA SV / EGRIFTA WR
Catalog approval status
Not represented as an FDA-approved drug product
Approved-product equivalence
Not represented or established
Scope of this reference

Approved-product labeling is linked only to distinguish the public regulatory record from this catalog listing. It is not reproduced as dosing, preparation, reconstitution, administration, personal-use, or medical guidance for this material.

External public records

DailyMed · FDA-label search for tesamorelin

FDA · EGRIFTA WR prescribing information

English original · 48 pages

Open PDF

Spanish translation · 104 pages · 5.8 MB

Open Spanish PDF Download Spanish PDF

Spanish translation prepared by Encore, not issued, reviewed or approved by the FDA or the manufacturer. Translates the March 2025 source linked above, with all 48 original pages included for comparison. This reference concerns the branded prescription product only; it is not use guidance for Encore catalog material. Consult the official record for updates.

03 / Supporting records

Documentation.

Read the Encore summary, the scope of related reports and the status of privacy-redacted supplier copies.

No authenticated certificate establishing current-inventory identity or specifications is published for Tesamorelin in this catalog.

Encore documentary summary · not a laboratory-issued COA

View Tesamorelin PDF downloads ↓
Report availability
3 related reports located
Formats & scope
Related reports name Tesamorelin 10 mg samples.
Report authenticity
Laboratory authentication pending
Inventory evidence review
Report-to-inventory correspondence has not been independently established. No purity, quantity or activity result is attributed to current inventory.
Outstanding review
Keep samples separate and review the retained source URL for privacy before release. Authenticate each report independently.
Product-specific SDS
Not located in the reviewed PDF set; applicability and verification pending.

Document inventory reviewed October 6, 2026. Related reports were commissioned by third parties, not Encore. Original customer details and internal records are not included here.

Privacy-redacted supplier report

Supplier-provided laboratory report

Where prepared, these are copies redacted by Encore for privacy, not laboratory-issued public versions or Encore-commissioned tests. Analytical content is not replaced with Encore results.

Tesamorelin · Related reports

2 reports · PDF available

English original · 4 pages · 3.6 MB

Open PDF Download PDF

Spanish translation · 8 pages · 3.6 MB

Open Spanish PDF Download Spanish PDF

Open PDF uses a new tab. Download PDF saves the same privacy-redacted packet.

Prepared by Encore; not issued or certified by the laboratory. Each translated page is followed by its English source page, preserving original graphs and signatures. The separate English original is unchanged.

Included scope and exclusions: Selected reports name 10 mg samples. Keep their sample findings separate. A separate report with a retained source URL is not included while its privacy exposure remains under review.

Laboratory authentication pending. These related references are not independently authenticated certificates for current Encore inventory. Supplier confirmation does not resolve the scope or discrepancies listed above.

Copy preparation
3 source files in redacted review copies. Duplicate file formats are not additional tests.
Supplier sharing permission
Owner-confirmed for supplied reports; this does not imply a report exists for every product. Report authentication is a separate check.
Privacy review
Selected website copy redacted; residual identification risk remains. Retained references and copies elsewhere can still identify the original customer; redaction does not guarantee anonymity.
Downloads
Selected related-reference PDF available.
Laboratory-issued public copy
Not available. Encore-prepared redactions are not an issuer reissue.

Read the packet cover and each report’s scope and limitations. Outstanding review items above remain unresolved; PDF availability does not change verification status.

A public copy does not by itself verify current inventory. No laboratory replacement or delivery date is promised.

Explore summary & report status

04 / A closer look

Common questions.

01Which Tesamorelin formats and reference prices are listed?

10 mg: $75 USD. These are catalog quantities and reference prices, not usage instructions, stock confirmation or an offer for sale.

02Where can I find the Tesamorelin reports?

The Documentation section on this page includes Open PDF and Download PDF links to a 4-page English original containing 2 supplier-provided reports. Read the covered sample formats and limitations beside the download. These privacy-redacted, third-party-commissioned copies are not laboratory reissues. Laboratory authentication and independent inventory review remain pending.

03Is this catalog material EGRIFTA SV or EGRIFTA WR?

No. FDA-approved prescription drug products containing tesamorelin exist under the EGRIFTA brand, but this catalog material is not represented as EGRIFTA, as an approved drug product, or as equivalent or substitutable.

04Does the FDA-approved EGRIFTA labeling apply to this catalog material?

No. FDA-approved labeling applies to the specific approved product and formulation described in that labeling. It does not establish the formulation, sterility, potency, manufacturing controls, quality, or intended use of this catalog material.

05Does this page provide dosing, reconstitution, preparation, or administration guidance?

No. This catalog does not provide dosing, reconstitution, preparation, administration, personal-use, or medical guidance. Listed quantities are catalog formats only.

06Does the image establish the contents of a lot?

No. The image is owned Encore Bio Labs reference artwork and may show legacy packaging. Use the written identity and specifications, then verify the exact lot with supporting records.

Continue the collection

Next in the catalog.

View all materials